Piper Sandler on GeneDx (WGS): 'Visibility to a Multiyear Growth Cycle'

August 4, 2025 10:19 AM EDT Send to a Friend
Piper Sandler analyst David Westenberg reiterated an Overweight rating and $120.00 price target on GeneDx (NASDAQ: WGS).The analyst commented: "Visibility ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login